Novartis seeks predictable interpretation of law in high octane Indian Glivec case
This article was originally published in Scrip
The crucial Indian patent case concerning Novartis' anticancer Glivec (imatinib mesylate) and its rejection due to Section 3(d), a controversial provision in India's patent law, comes up for hearing next week, amid hope and concern for the parties involved.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.